InsiderClue
Insiders · Profile

Henderson Molly

CFO and CBO at Phathom Pharmaceuticals · Chief Financial Officer at UroGen Pharma. Filing since 17 May 2021. CIK 0001363812

PHAT Phathom Pharmaceuticals, Inc. CFO and CBO · 14 trades URGN UroGen Pharma Ltd. Chief Financial Officer · 3 trades
Company
Date
Role
Action
Shares
Amount
Of holding
PHAT Phathom Pharmaceuticals, Inc.
7 Apr 2025
CFO and CBO
Sold at will
3,678
$16.74K
3.9%
PHAT Phathom Pharmaceuticals, Inc.
21 Jan 2025
CFO and CBO
Sold at will
6,583
$43.37K
6.6%
PHAT Phathom Pharmaceuticals, Inc.
19 Dec 2024
CFO and CBO
Sold at will
1,291
$10.33K
1.3%
PHAT Phathom Pharmaceuticals, Inc.
15 Jul 2024
CFO and CBO
Sold at will
4,325
$50.69K
4.2%
PHAT Phathom Pharmaceuticals, Inc.
8 Apr 2024
CFO and CBO
Sold at will
3,435
$38.13K
3.5%
PHAT Phathom Pharmaceuticals, Inc.
19 Jan 2024
CFO and CBO
Sold at will
6,307
$48.90K
6.0%
PHAT Phathom Pharmaceuticals, Inc.
20 Nov 2023
CFO and CBO
Sold at will
2,127
$15.40K
2.0%
PHAT Phathom Pharmaceuticals, Inc.
1 Nov 2023
CFO and CBO
Sold at will
12,492
$110.87K
10.6%
PHAT Phathom Pharmaceuticals, Inc.
2 Jun 2023
CFO and CBO
Sold on a plan
1,960
$22.37K
2.8%
PHAT Phathom Pharmaceuticals, Inc.
22 May 2023
CFO and CBO
Sold on a plan
2,110
$27.16K
2.9%
PHAT Phathom Pharmaceuticals, Inc.
6 Apr 2023
CFO and CBO
Sold on a plan
3,439
$25.00K
4.5%
PHAT Phathom Pharmaceuticals, Inc.
1 Mar 2023
CFO and CBO
Sold, plan not stated
2,032
$17.33K
2.6%
PHAT Phathom Pharmaceuticals, Inc.
21 Nov 2022
CFO and CBO
Sold, plan not stated
2,159
$20.73K
4.7%
PHAT Phathom Pharmaceuticals, Inc.
13 May 2022
CFO and CBO
Bought
6,000
no price
30.0%
URGN UroGen Pharma Ltd.
31 Jan 2022
Chief Financial Officer
Sold, plan not stated
331
$2.51K
5.9%
URGN UroGen Pharma Ltd.
30 Nov 2021
Chief Financial Officer
Sold, plan not stated
2,587
$31.12K
34.5%
URGN UroGen Pharma Ltd.
17 May 2021
Chief Financial Officer
Bought
2,500
$39.63K
opened
17 decisions on file.